Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

BACKGROUND: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20–30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our study's aim is to investigate the association of the ceramide-sphi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., Horvath, Lisa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526762/
https://www.ncbi.nlm.nih.gov/pubmed/34656931
http://dx.doi.org/10.1016/j.ebiom.2021.103625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526762/
https://www.ncbi.nlm.nih.gov/pubmed/34656931
http://dx.doi.org/10.1016/j.ebiom.2021.103625

Ejemplares similares